Mid Cap Emerging Biopharmaceutical Companies: Valuations Do Matte
Valuation Models for Biopharma Stocks -M&A Update In October 2013 we compared emerging biotech stocks after the acquistion of Onyxx Pharmaceuticals by Amgen (AMGN). Now that rumors are “out there” for the acquisition of Pharmacyclics (PCYC) by large healthcare companies such as Johnson and Johnson (JNJ) and Novartis (NVS) we can compare valuations. The $11B++ range is…